Basic Principles of Antineoplastic Therapies

  • Tufia Haddad
  • Douglas Yee


Antineoplastic therapies can be classified as either cytotoxic systemic chemotherapy or targeted biological therapy. In many ways, cytotoxic chemotherapy is “targeted” at specific molecules that regulate progression through the cell cycle; however, these targets are generally not specific for tumor cells. Because systemic cytotoxic chemotherapy targets all rapidly dividing cells, it also attacks hair follicles, gastrointestinal mucosa, and hematopoietic cells thereby inducing the classical side effects of treatment such as alopecia, nausea, diarrhea, mucositis, and bone marrow suppression. The newer generation of targeted biological therapies is still administered systemically as traditional chemotherapy; however, these drugs are unique in that they are designed to target specific molecular components in tumor cell biology with the hope of minimizing cytotoxicity to noncancerous cells. In addition, they have toxicities specific to their mechanism of action. This chapter provides an overview of the biology of systemic therapy for breast cancer.


Breast Cancer Human Epidermal Growth Factor Receptor Antineoplastic Therapy Growth Fraction Tumor Cell Biology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Goldie J. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol. 1987;14:1.PubMedGoogle Scholar
  2. 2.
    DeVita V. The evolution of therapeutic research in cancer. N Engl J Med. 1978;298:907.PubMedCrossRefGoogle Scholar
  3. 3.
    Skipper H, Schabel F, Mellet L, et al. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1950;54:431.Google Scholar
  4. 4.
    Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48:7067.PubMedGoogle Scholar
  5. 5.
    Citron M, Berry D, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Glaspy J. Hematopoietic management in oncology practice. Part 1. Myeloid Growth Factors. Oncology. 2003;17:1593.PubMedGoogle Scholar
  7. 7.
    Atkinson A, Daniels C, Dedrick R, et al. Principles of clinical pharmacology. San Diego: Academic; 2001.Google Scholar
  8. 8.
    Ratain M, Mick R. Principles of pharmacokinetics and pharmacodynamics. New York: Marcel Dekker; 1996.Google Scholar
  9. 9.
    Evans W, McLeod H. Pharmacogenomics- drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538.PubMedCrossRefGoogle Scholar
  10. 10.
    Goetz M, Rae J, Suman V, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312–8.PubMedCrossRefGoogle Scholar
  11. 2010.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  12. 12.
    Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC trial efficacy and safety update analyses. Cancer. 2003;98:1802–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Ingle J, Suman V, Rowland K, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006;24(7):1052–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.PubMedGoogle Scholar
  16. 16.
    Geyer C, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. NEJM. 2007;357(26):2666–2676.Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Departments of Medicine and PharmacologyUniversity of MinnesotaMinneapolisUSA

Personalised recommendations